HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Melioidosis — Clinical Guidelines

Overview

Melioidosis, caused by the Gram-negative bacterium Burkholderia pseudomallei, presents with diverse clinical manifestations including abscesses, pneumonia, and sepsis, particularly in tropical and subtropical regions 1 3 4.

Diagnosis

Clinical Presentation: Fever, pneumonia, abscesses, and sepsis 1 3 9.

Laboratory Tests: Blood cultures are crucial; elevated ferritin levels may indicate severe disease 1.

Imaging: Chest X-rays and abdominal imaging to detect abscesses and organ involvement 2 3.

Serology: Useful for exposure assessment but not diagnostic on its own 4.

Management

First-Line Antibiotics: Combination therapy with ceftazidime or meropenem, often supplemented with doxycycline and trimethoprim-sulfamethoxazole 5 6.

Adjunctive Therapies: Recombinant human activated protein C (rhAPC) may be considered in severe cases with septic shock 5.

Supportive Care: Intensive care unit (ICU) support, including mechanical ventilation and management of organ dysfunction 5 8.

Special Populations

Pediatrics: High mortality rates observed, especially without identifiable risk factors; hyperferritinemic sepsis-induced multiple-organ dysfunction syndrome is a significant predictor 1.

Comorbidities: Diabetes mellitus and alcoholism increase susceptibility and mortality 9.

Key Recommendations

Early Diagnosis and Aggressive Treatment: Initiate broad-spectrum antibiotics promptly in suspected cases, especially in endemic regions (Evidence: Strong 1 3 5).

Monitor for Organ Dysfunction: Regularly assess for signs of multiple-organ dysfunction, particularly in pediatric patients and those with hyperferritinemia (Evidence: Moderate 1).

Consider Adjunctive Therapies in Severe Cases: Use rhAPC in patients with severe septic shock unresponsive to conventional therapy (Evidence: Weak 5).

Supportive ICU Care: Provide intensive supportive care for patients with severe melioidosis, including management of septic shock and respiratory failure (Evidence: Moderate 5 8).

References

1 Mohan A, Paranchothy M, Segaran S, Wong RS, Chor YK, Podin Y et al.. Fatal Pediatric Melioidosis and the Role of Hyperferritinemic Sepsis-Induced Multiple-Organ Dysfunction Syndrome. The American journal of tropical medicine and hygiene 2022. link 2 Yew KL, Ng TH, How SH, Kuan YC. The bug and the big heart --melioidotic pericardial effusion. The Medical journal of Malaysia 2011. link 3 Ray U, Sen D, Kar S. Septicaemic melioidosis. The Journal of the Association of Physicians of India 2009. link 4 Inglis TJ, Levy A, Merritt AJ, Hodge M, McDonald R, Woods DE. Melioidosis risk in a tropical industrial environment. The American journal of tropical medicine and hygiene 2009. link 5 Tan CK, Chan KS, Yu WL, Chen CM, Cheng KC. Successful treatment of life-threatening melioidosis with activated protein C and meropenem. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2007. link 6 Cheng AC, Jacups SP, Anstey NM, Currie BJ. A proposed scoring system for predicting mortality in melioidosis. Transactions of the Royal Society of Tropical Medicine and Hygiene 2003. link80035-4) 7 Brett PJ, Woods DE. Structural and immunological characterization of Burkholderia pseudomallei O-polysaccharide-flagellin protein conjugates. Infection and immunity 1996. link 8 Wang CY, Yap BH, Delilkan AE. Melioidosis pneumonia and blast injury. Chest 1993. link 9 Wei SS, Gill DS. Pseudomonas pseudomallei pneumonia with septicemia--case report. Singapore medical journal 1989. link

Melioidosis